India
-
News
Drugs: WHO prequalifies generic active ingredient for new anti-hepatitis drugs
"Sofosbuvir - recalls the WHO - is an essential ingredient for new highly effective drugs against hepatitis C" by…
Leggi » -
First floor
EMA recommends the suspension of 342 generic medicines due to the unreliability of Indian bioequivalence studies. Ed
EMA Recommends Drug Suspension Due to Unreliable Studies from Micro Therapeutic Research Labs EMA – Press…
Leggi » -
News
Hepatitis C, Milanese pensioner wins legal battle: low-cost life-saving drugs from India
Medicines purchased online at one-thirtieth of the cost in Italy were stopped at customs and once released "for ...
Leggi » -
News
AIFA. Generic metformin cautionary recall made in India
Cautionary withdrawal of lots of METFORMIN MYLAN Generic tablets (various dosages) The Italian Medicines Agency (AIFA) announces that it has approved the withdrawal…
Leggi » -
News
Hepatitis C, yes of the judge to the life-saving drug bought abroad
The ordinance. The Court of Appeal of Rome agrees with a patient who had purchased the treatment in India THE RECIPE…
Leggi » -
News
EMA recommends suspension for medicines whose bioequivalence studies were conducted at the Semler Research Center site - Bangalore - India
The European Medicines Agency (EMA) has recommended the suspension in the EU of all [generic] medicines approved or in the process of…
Leggi » -
News
One in 5 doctors follows patients who have bought a generic anti-HCV
Gardini, fenomeno dilagante frutto delle attuali limitazioni di accesso a cure innovative. Il 79% dei medici si dice favorevole alla…
Leggi » -
News
AIFA. Suspended Indian generics Lovastatin, Simvastatin
Sospensione CEP: R1-CEP 2004-026-Rev 01/LOVASTATIN; R1-CEP 2004-051-Rev 02/SIMVASTATIN; R1-CEP 2007-210-Rev 00/SIMVASTATIN; R1-CEP 2005-242-Rev 01/SIMVASTATIN (30/05/2016) AIFA – Avviso alle Aziende…
Leggi » -
News
Drugs, India grants anti-hepatitis C patent
Gilead Sciences ha ottenuto dall’Ufficio Brevetti indiano l’approvazione per la protezione commerciale sul farmaco anti-epatite C Sovaldi* (sofosbuvir). Una vittoria…
Leggi » -
News
Hepatitis C: the patent case of Gilead's drug sofosbuvir opens in India
L’ufficio dei brevetti indiano inizia oggi le udienze per stabilire se l’azienda farmaceutica statunitense Gilead Sciences abbia diritto al brevetto…
Leggi »